Prothrombotic fibrin clot phenotype as a risk factor for persistent left ventricular thrombus following acute myocardial infarction
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.06.003 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Krystian Mróz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Department of Interventional Cardiology, St. John Paul II Hospital, Kraków, Poland. Hauptthemen laut MEDLINE: Fibrin, Fibrin Clot Lysis Time, Heart Diseases, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Uniwersytet Jagielloński Collegium Medicum.
Abstract (Originalsprache)
BACKGROUND: Left ventricular thrombus (LVT) occurs in up to 15% of ST-segment elevation myocardial infarction (MI) patients and may persist in 30% despite anticoagulation. We hypothesized that formation of dense and poorly lysable fibrin clots may contribute to this phenomenon. OBJECTIVES: We investigated whether unfavorable fibrin clot properties and their determinants are associated with resolution of LVT on anticoagulation. METHODS: We included 149 consecutive patients with LVT during acute MI referred for diagnostic workup. Three months after MI, we determined plasma fibrin clot permeability (Ks), clot lysis time (CLT), and plasminogen activator inhibitor-1, along with citrullinated histone H3, a marker of NETosis. LVT resolution was assessed on enrollment (after 3 months of anticoagulation, mostly with direct oral anticoagulants [n = 121, 82%]) and 3 months thereafter. RESULTS: Patients with LVT visible at 3 months (n = 75, 50.3%) were characterized by lower Ks (-15.5%) and longer CLT (+30%), along with higher plasminogen activator inhibitor-1 (+42.4%) and citrullinated histone H3 (+33.3%), without differences in the type of anticoagulation. At 6 months after MI on continued anticoagulation, LVT was visible in 44 (29.7%) of patients, who had an unfavorable clot phenotype compared with individuals with resolved LVT. Lower Ks and longer CLT were associated with LVT persistence at 3 and 6 months, irrespective of potential confounding factors. CONCLUSIONS: This is the first study to demonstrate that prothrombotic fibrin clot properties, which might be related to enhanced NETosis, are associated with anticoagulation failure in patients with LVT complicating acute MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Department of Interventional Cardiology, St. John Paul II Hospital, Kraków, Poland.
- Clinical Department of Interventional Cardiology, St. John Paul II Hospital, Kraków, Poland; Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland.
- Department of Epidemiology and Population Studies, Jagiellonian University Medical College, Kraków, Poland.
- Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland; Krakow Center for Medical Research and Technologies, St. John Paul II Hospital, Kraków, Poland. E…
Förderung
- Uniwersytet Jagielloński Collegium Medicum
Zitieren
APA
Mróz, K., Paszek, E., Polak, M., & Undas, A. (2025). Prothrombotic fibrin clot phenotype as a risk factor for persistent left ventricular thrombus following acute myocardial infarction. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.06.003
Vancouver
Mróz K, Paszek E, Polak M, Undas A. Prothrombotic fibrin clot phenotype as a risk factor for persistent left ventricular thrombus following acute myocardial infarction. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.06.003
BibTeX
@article{Mrz2025,
author = {Mróz, Krystian and Paszek, Elżbieta and Polak, Maciej and Undas, Anetta},
title = {Prothrombotic fibrin clot phenotype as a risk factor for persistent left ventricular thrombus following acute myocardial infarction},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.06.003}
}
EUVIMED